Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level

被引：3
|
作者：
Bazhenova, L. [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92037 USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 04期
关键词：
1ST-LINE NIVOLUMAB; PLUS IPILIMUMAB; ADENOCARCINOMA; CHEMOTHERAPY; SENSITIVITY; ASSOCIATION; EFFICACY; OUTCOMES; NSCLC;
D O I：
10.1016/j.annonc.2023.02.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level (vol 34, pg 327, 2023 )
    Bazhenova, L.
    ANNALS OF ONCOLOGY, 2023, 34 (08) : 725 - 726
  • [2] Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer
    Sumii, Masahiko
    Namba, Masashi
    Tokumo, Kentaro
    Yamauchi, Masami
    Okamoto, Wataru
    Hattori, Noboru
    Sugiyama, Kazuhiko
    INTERNAL MEDICINE, 2023, 62 (20) : 3001 - 3004
  • [3] Emerging insights into STK11, KEAP1 and KRAS mutations: implications for immunotherapy in patients with advanced non-small cell lung cancer
    Knetki-Wroblewska, Magdalena
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    Krzakowski, Maciej
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12) : 3718 - 3730
  • [4] The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC)
    Cheung, T. W.
    Morales, J.
    Sacks, H.
    Rolfo, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S630 - S630
  • [5] Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
    Nie, Wei
    Gan, Lu
    Wang, Xin
    Gu, Kai
    Qian, Fang-Fei
    Hu, Min-Juan
    Zhang, Ding
    Chen, Shi-Qing
    Lu, Jun
    Cao, Shu-Hui
    Li, Jing-Wen
    Wang, Yue
    Zhang, Bo
    Wang, Shu-Yuan
    Li, Chang-Hui
    Yang, Ping
    Xu, Mi-Die
    Zhang, Xue-Yan
    Zhong, Hua
    Han, Bao-Hui
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [6] STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Di Federico, Alessandro
    De Giglio, Andrea
    Parisi, Claudia
    Gelsomino, Francesco
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 108 - 113
  • [7] Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-) mutations in non-small cell lung cancer with a special focus on KRAS G12C
    Boeschen, Myriam
    Kuhn, Christina Katharina
    Wirtz, Hubert
    Seyfarth, Hans-Jurgen
    Frille, Armin
    Lordick, Florian
    Hacker, Ulrich T.
    Obeck, Ulrike
    Stiller, Mathias
    Blaker, Hendrik
    von Laffert, Maximilian
    LUNG CANCER, 2023, 184
  • [8] STK11, KEAP1, and KRAS mutation epidemiology and real-world outcomes in US patients with newly diagnosed metastatic non-small cell lung cancer
    Dabbous, Firas
    Wang, Ching-Yu
    Ghosh, Rajrupa
    Hsieh, Kristin
    Simmons, Daniel
    Huse, Samuel
    Jassim, Rami
    Skoulidis, Ferdinandos
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E42 - E42
  • [9] Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer
    Dabbous, Firas
    Wang, Ching-Yu
    Simmons, Daniel
    Huse, Samuel
    Jassim, Rami
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Comparison of STK11 and KEAP1 Mutation Detection in Circulating Tumor DNA (ctDNA) and Tissue from Patients with Non-Squamous Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
    Lai, Z.
    Barrett, J.
    Stewart, R.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : S133 - S134
12345